Biotech Pulse: Tau Drugs, SSRI Tapers, and a Sanofi Wearable Win
TL;DR Summary
A Readout newsletter recap notes buzz around daraxonrasib and tau therapies at major meetings, U.S. HHS is drafting guidance on tapering SSRIs, and the FDA cleared Sanofi’s wearable injector for a myeloma drug.
- All eyes on data on Biogen’s tau therapy STAT
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease Biogen
- An experimental Alzheimer's drug shows some promise as researchers hunt new approaches AP News
- Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows STAT
- Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details Barron's
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 2 min read
Condensed
90%
336 → 33 words
Want the full story? Read the original article
Read on STAT